here we report a novel approach for preparation of a 6-day transdermal drug delivery system (tdds) as treatment for mild to moderate alzheimer’s disease. the spray drying method was used to prepare microparticles containing the anti-alzheimer drug. the content of the drug was determined by high performance liquid chromatography (hplc) method. the morphology and size range of the microparticles ...

BACKGROUND The positive results of a randomised clinical trial of rivastigmine in patients with dementia associated with Parkinson's disease have been published recently. Patient-level healthcare utilisation data were also collected, and this report is the economic evaluation based on these data. OBJECTIVE To determine the cost effectiveness of rivastigmine 3-12 mg/day in patients in whom mil...

a simple and reproducible hplc method with spectrophotometric detection was developed for determination of rivastigmine in human plasma. liquid-liquid extraction of rivastigmine and donepezil (as internal standard) from plasma samples was performed with 1-butanol/n-hexane (2:98 v/v) in alkaline condition followed by back-extraction into diluted acetic acid. chromatography was carried out using ...

SUMMARY The ReSPonD trial was a single-centre, double-blind, placebo controlled phase 2 trial to investigate whether the acetylcholinesterase inhibitor rivastigmine would reduce gait variability in Parkinson's disease (PD). 1 A total of 130 patients with PD were randomised to receive twice daily oral rivastigmine or placebo for 32 weeks in a 1:1 ratio. Rivastigmine was uptitrated to a target do...

The main aim of the investigation was to explore a novel L-lactide-depsipeptide copolymer for the development of rivastigmine-loaded polymeric nanoparticles. L-lactide-depsipeptide synthesis was based on the ring opening polymerization reaction of L-lactide with the cyclodepsipeptide, cyclo(Glc-Leu), using tin 2-ethyl hexanoate as an initiator. Rivastigmine-loaded nanoparticles were prepared by...

BACKGROUND Cholinesterase inhibitors and glutamate blockers are commonly used for the treatment of cognitive impairment in Alzheimer's disease. The aim was to evaluate the effects of rivastigmine and memantine alone or in combination in rats with scopolamine-impaired memory. METHOD 5 groups of rats were used: control, scopolamine (model), model with rivastigmine, model with memantine, and mod...

OBJECTIVE To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD. METHODS Eleven patients with mild AD received rivastigmine for 12 months. Cholinesterase (ChE) activities in the CSF and plasma were assessed colorimetrically. Immunoblot analysis was used to evaluate AChE isoforms. Neuropsychiatric tes...

BACKGROUND/AIMS The purpose of this systematic review was to compare the safety and tolerability of the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine for treating mild to moderate Alzheimer's disease (AD) patients in routine clinical practice. METHODS Electronic databases (Cochrane Library, Medline, EMBASE; accessed October 2008) and manual bibliographic searches w...

BACKGROUND Sustained treatment with a cholinesterase inhibitor (ChEI) is used in the management of the symptoms of Alzheimer's disease (AD). However, the characteristic declines in learning and memory seen in AD may erode the patient's ability to adhere to medication regimens with or without caregiver support. OBJECTIVES To examine differences by type of ChEI in (1) monthly prevalence of use,...